Literature DB >> 16374979

Do creatine kinase (CK) levels influence the diagnosis or outcome in patients with compartment syndrome?

U Ihedioha1, S Sinha, A C Campbell.   

Abstract

We report a retrospective study in patients with compartment syndrome with the aim to analyse: 1) whether the level of rise in CK levels is a useful marker to the presence of compartment syndrome and; 2) whether an early fasciotomy assists in lowering of the elevated CK levels. The results of our study suggest that although raised CK levels are not diagnostic, they are a useful adjunct in making a diagnosis, and hence CK estimation should be done in all patients with suspected compartment syndrome. Moreover, an early fasciotomy (< 12 hours) has a statistically significant influence in lowering elevated CK levels, confirming the view that the earlier the decompression, the lesser the muscle damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16374979     DOI: 10.1177/003693300505000407

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  4 in total

1.  Spectral Doppler findings in a rare case of acute compartment syndrome following leg burn.

Authors:  Omer A Mahmoud; Mustafa Z Mahmoud
Journal:  Radiol Case Rep       Date:  2018-02-03

2.  A comparison of three different surgery approaches and methods for neurologically intact thoracolumbar fractures: a retrospective study.

Authors:  Chao Zhu; Bin Wang; Jian Yin; Xin Hui Liu
Journal:  J Orthop Surg Res       Date:  2021-05-10       Impact factor: 2.359

3.  Clinical and functional outcomes of acute lower extremity compartment syndrome at a Major Trauma Hospital.

Authors:  Loreto Lollo; Andreas Grabinsky
Journal:  Int J Crit Illn Inj Sci       Date:  2016 Jul-Sep

4.  Normalization of creatine kinase values in a case of rhabdomyolysis during daptomycin treatment.

Authors:  Olivia Ferrández; Olatz Urbina; Sònia Luque; Mercè Espona; Nuria Berenguer; Santiago Grau
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.